Salubrinal
From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
 | This article is a stub. |
Salubrinal is a new, unlicensed and unapproved drug which is being explored as a potential treatment for fatigue and extercise intolerance in ME/CFS and Long Covid.[1]
Salubrinal suppresses production of the protein WASF3, which has been implicated in fatigue and exercise intolerance in patients with ME/CFS.[1]
Evidence[edit | edit source]
Notable studies[edit | edit source]
- 2025, Assessment of the therapeutic potential of salubrinal for ME/CFS and long-COVID[1] - (Abstract)
Clinicians[edit | edit source]
Risks and safety[edit | edit source]
Cost and availability[edit | edit source]
See also[edit | edit source]
Learn more[edit | edit source]
References[edit | edit source]
- ↑ 1.0 1.1 1.2 Warrayat, Aseel; Ali, Ayah; Waked, Joulin; Tocci, Darcy; Speth, Robert C. (May 2025). "Assessment of the therapeutic potential of salubrinal for ME/CFS and long-COVID". Trends in Molecular Medicine. 31 (5): 466–478. doi:10.1016/j.molmed.2024.10.001. ISSN 1471-4914.
